No phaseCompleted
AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of AMAZ-02 on Muscle Function in Otherwise Healthy Middle-aged, Overweight and Inactive Individuals
- Sponsor
- Amazentis SA (Industry)
- Enrolment
- 90 enrolled
- Conditions
- Muscle Function, Mitochondrial Function; Overweight; Healthy Aging
- Interventions
- Mitopure 500mg; Mitopure 1000mg; Placebo
- Ages
- adults, older adults
- Registry
- NCT03464500
From the registry
This is a Phase 2 randomized, double-blind, placebo-controlled study enrolling 90 healthy, overweight, middle aged subjects (30 placebo, 30 low dose and 30 high dose AMAZ-02 intervention), 40-65 years of age, who are otherwise healthy. AMAZ-02, a food derived ingredient, will be given as a daily oral dose for 4 months.
Primary outcomes
- Change in exercise tolerance as assessed by power output on the cycle ergometer from baseline to day 120 between AMAZ-02 groups and placebo